Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (PLX) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST
Company Participants
Mike Moyer – Managing Director
Dror Bashan – President, CEO & Director
Gilad Mamlok – Senior VP, CFO Treasurer & Secretary
Conference Call Participants
Raghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division
John Vandermosten – Zacks Small-Cap Research
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded.
I will now turn the conference over to our host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protalix. Thank you. Please go ahead.
Mike Moyer
Managing Director
Thank you, operator, and welcome to the Protalix BioTherapeutics Third Quarter 2026 Financial Results and Business Update Conference Call.
With me today are Dror Bashan, President and CEO, and Gilad Mamlok, Senior Vice President and Chief Financial Officer.
A press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings and this teleconference include forward-looking statements.
These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Dror?
Dror Bashan
President, CEO & Director
Thank you, Mike, and thank you, everyone, for joining us for this call. We concluded the first 9 months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial position, which supports our ability to execute our strategy and advance our key
